Recombinant human endostatin (endostar) decreased recurrent ascites, pleural fluid and ascitic VEGF in a case of advanced mesothelioma

Journal of Chemotherapy

Volumn 24, Issue 4, 2012, Pages 231-236

  Chen, Xiaofeng ^a   Liu, Yiqian ^a   Yin, Yongmei ^a   Jin, Shidai ^a   Ping, Guoqian ^a   Røe, Oluf D ^b,c   Yan, Keli ^a   Shu, Yongqian ^a   Guo, Renhua ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^c Levanger Hospital   (Norway)

Author keywords

Chemotherapy; Endostatin; Maintenance therapy; Malignant mesothelioma; Vascular endothelial growth factor

Indexed keywords

CALRETININ; CISPLATIN; CYTOKERATIN 5; CYTOKERATIN 6; EPITHELIAL MEMBRANE ANTIGEN; FLUORODEOXYGLUCOSE; GEMCITABINE; PEMETREXED; RECOMBINANT ENDOSTATIN; VASCULOTROPIN; VIMENTIN;

ADULT; ADVANCED CANCER; ANEMIA; ARTICLE; ASCITES; ASCITES FLUID CYTOLOGY; ASCITES FLUID LEVEL; ASPIRATION; BLOOD CELL COUNT; BONE MARROW SUPPRESSION; CASE REPORT; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CHINESE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DRUG UPTAKE; DYSPNEA; FATIGUE; GREATER OMENTUM; HOSPITAL ADMISSION; HUMAN; IMMUNOHISTOCHEMISTRY; LAPAROSCOPY; MALE; MALIGNANT MESOTHELIOMA; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PERITONEAL BIOPSY; PERITONEAL FLUID; PLEURA FLUID; PROGRESSION FREE SURVIVAL; RECURRENT DISEASE; STOMACH DISTENSION;

ADULT; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASCITES; ASCITIC FLUID; CISPLATIN; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; ENDOSTATINS; HUMANS; LUNG NEOPLASMS; MALE; MESOTHELIOMA; NEOPLASM STAGING; PLEURAL EFFUSION, MALIGNANT; RECOMBINANT PROTEINS; RECURRENCE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84866242435     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/1973947812Y.0000000023     Document Type: Article

References (24)

1. Roberts WG, Palade GE. Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J Cell Sci. 1995;108 (Pt 6):2369-79.
2. Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet. 2005;366:397-408.
3. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636-44.
4. Pasello G, Favaretto A. Molecular targets in malignant pleural mesothelioma treatment. Curr Drug Targets. 2009;10:1235-44.
5. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997;88:277-85.
6. Folkman J. Antiangiogenesis in cancer therapy - endostatin and its mechanisms of action. Exp Cell Res. 2006;312:594-607.
7. Kim YM, Hwang S, Pyun BJ, Kim TY, Lee ST, Gho YS, et al. Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1. J Biol Chem. 2002;277:27872-9.
8. Hajitou A, Grignet C, Devy L, Berndt S, Blacher S, Deroanne CF, et al. The antitumoral effect of endostatin and angiostatin is associated with a down-regulation of vascular endothelial growth factor expression in tumor cells. FASEB J. 2002;16:1802-4.
9. Wang J, Sun Y, Liu Y, Yu Q, Zhang Y, Li K, et al. Results of randomized, multicenter, double-blind phase III trial of rhendostatin (YH-16) in treatment of advanced non-small cell lung cancer patients. Zhongguo Fei Ai Za Zhi. 2005;8:283-90. Chinese.
10. Jia H, Kling J. China offers alternative gateway for experimental drugs. Nat Biotechnol. 2006;24:117-8.
11. Van Meerbeeck JP, Scherpereel A, Surmont VF, Baas P. Malignant pleural mesothelioma: The standard of care and challenges for future management. Crit Rev Oncol Hematol. 2011;78:92-111.
12. Feng D, Nagy JA, Hipp J, Dvorak HF, Dvorak AM. Vesiculo-vacuolar organelles and the regulation of venule permeability to macromolecules by vascular permeability factor, histamine, and serotonin. J Exp Med. 1996;183:1981-6.
13. Esser S, Wolburg K, Wolburg H, Breier G, Kurzchalia T, Risau W. Vascular endothelial growth factor induces endothelial fenestrations in vitro. J Cell Biol. 1998;140:947-59.
14. Yasumitsu A, Tabata C, Tabata R, Hirayama N, Murakami A, Yamada S, et al. Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma. J Thorac Oncol. 2010;5:479-83.
15. Hirayama N TC, Tabata R, Maeda R, Yasumitsu A, Yamada S, Kuribayashi K, et al. Pleural effusion VEGF levels as a prognostic factor of malignant pleural mesothelioma. Respir Med. 2011;105:137-42.
16. Li Q, Yano S, Ogino H, Wang W, Uehara H, Nishioka Y, et al. The therapeutic efficacy of anti vascular endothelial growth factor antibody, bevacizumab, and pemetrexed against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice. Clin Cancer Res. 2007;13:5918-25.
17. Karrison T, Kindler HL, Gandara DR, Lu C, Guterz TL, Nichols K, Chen H, et al. Final analysis of a multi-center, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients (pts) with malignant mesothelioma (MM). J Clin Oncol. 2007;25(18 suppl) abstract 7526.
18. Jackman DM, Kindler HL, Yeap BY, Fidias P, Salgia R, Lucca J, et al. Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma. Cancer. 2008;113:808-14.
19. Nasreen N, Mohammed KA, Brown S, Su Y, Sriram PS, Moudgil B, et al. Talc mediates angiostasis in malignant pleural effusions via endostatin induction. Eur Respir J. 2007;29:761-9.
20. Rusch VW, Niedzwiecki D, Tao Y, Menendez-Botet C, Dnistrian A, Kelsen D, et al. Intrapleural cisplatin and mitomycin for malignant mesothelioma following pleurectomy: pharmacokinetic studies. J Clin Oncol. 1992;10(6):1001-6.
21. Zhang X, Zang J, Xu J, Bai C, Qin Y, Liu K, et al. Maintenance therapy with continuous or switch strategy in advanced non-small-cell lung cancer: a systematic review and meta-analysis. Chest. 2011;140(1):117-26.
22. Giuliani F, de Vita F, Colucci G, Pisconti S. Maintenance therapy in colon cancer. Cancer Treat Rev. 2010;36Suppl 3: S42-45.
23. Grothey A SM, Purdie DM, Dong W, Sargent D, Hedrick E, Kozloff M. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol. 2008;28:5326-34.
24. Roe OD, Anderssen E, Sandeck H, Christensen T, Larsson E, Lundgren S. Malignant pleural mesothelioma: genome-wide expression patterns reflecting general resistance mechanisms and a proposal of novel targets. Lung Cancer. 2010;67:57-68.